Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis

Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis

GA Depot Patent Release – May 27 2014

Ness Ziona, Israel, May 27, 2014 —- Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs, announced today that its US patent for the company’s Glatiramer Acetate Depot has been extended until December 2030.

 

The notice of allowance for US Patent Application No. 13/258,808 entitled Depot Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof, also awarded additional claims to an earlier patent (U.S. Patent 8,377,885), issued to the company in February 2013.  

 

The additional claims include:

  • administration from about two weeks to about once-a-month for glatiramer salts, including glatiramer acetate;
  • administration from about once-a-week to about six months for salts other than glatiramer acetate; and,
  • glatiramer salts Depot, including glatiramer acetate, in combination with at least one additional drug.

 

The Glatiramer Acetate Depot formulation is a Life Cycle Management product of Copaxone® to be injected between once-a-week and up to once-every-six-months subcutaneously (under the skin) or intramuscularly (into the muscle) for prolonged release of the therapeutic agent, thereby allowing for increased compliance and a reduced burden of treatment.

 

MS is a chronic, often disabling disease that attacks the central nervous system. Symptoms include numbness in the limbs, paralysis and loss of vision. Symptoms are unpredictable and differ from one person to another. According to Thomson Reuters Cortellis’ website, the global market for MS pharmaceuticals is estimated to be approximately US $15 billion.